Sample and treatment hypothesis
Review tumor type, sample state, prior treatment and the immune process the candidate is intended to change.
Application
PDO 2.0 studies for immunotherapy
Use PDO 2.0 / ALI and project-relevant immune assays to study relationships among immune composition, architecture and treatment response.
PDO 2.0 immune studies
Observe immune baseline and treatment response
A renal PDO 2.0 study shows tissue and ICB-related flow results; a separate NSCLC study shows CD4/CD8 counts under IL-2 conditions. Together, they illustrate how immune readouts can be selected for each sample and treatment mechanism.
View imageTissue and model context: PanCK, CD3 and DAPI imaging compares tumor-epithelial and CD3-positive immune-cell signals across the source tissue and PDO culture time points.
TRiCBIO ccRCC PDO 2.0 immune-context study data
View imageChanges after immune-checkpoint blockade: flow cytometry measures PD-L1, CD8, CD56, early apoptosis and necrosis to compare immune profiles and cell death across treatment conditions.
TRiCBIO ccRCC PDO 2.0 immune-context study data
View imageT-cell analysis in NSCLC PDO 2.0: CD4/CD8 counts within CD3-positive tumor-infiltrating lymphocytes are compared across IL-2 conditions. LC-1 to LC-4 were assessed at day 7 and LC-5 at day 28.
TRiCBIO NSCLC PDO 2.0 study dataReview the full study
View the TME study Continue to the related case for model context, experimental setup and interpretation.
Study focus
Questions we can help answer
- 01Which immune components are reliably measurable?
- 02How does treatment affect activation and cytotoxicity?
- 03Which multimodal readouts support single-agent and combination comparisons?
Study workflow
From study goal to results
Model and immune baseline
Select PDO 2.0 / ALI or a custom co-culture, then confirm tissue identity and measurable immune components.
Treatment and multimodal readouts
Combine histology, flow, apoptosis, cytokine or TCR readouts according to mechanism.
Integrated interpretation
Interpret tumor response and immune change against model baseline and define recommended follow-up studies.
Model options
Models for your study
At study start, baseline QC confirms measurable immune components and the culture window, guiding treatment conditions and endpoint selection.
PROJECT DISCUSSION
Plan an organoid immunotherapy study
Tumor type, sample condition, treatment mechanism and the immune response of interest guide the choice of PDO 2.0 / ALI or a custom co-culture, controls and readouts.